We have a number of clinical trials evaluating investigational RAS(ON) inhibitors.
RASolute 305
Phase 3 Study of Zoldonrasib (RMC‑9805) as First-line Treatment in Patients With Metastatic KRAS G12D Mutant Pancreatic Adenocarcinoma (RASolute 305)
Active, RECRUITING
3 (double blind)
Pancreatic adenocarcinoma
3
RASolute 303
Phase 3 Study of First-Line Daraxonrasib (RMC-6236) and Gemcitabine + Nab-Paclitaxel as Monotherapy or as Combination Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Active, RECRUITING
3 (open-label)
Pancreatic adenocarcinoma
3
RASolute 304
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Active, RECRUITING
3 (open-label)
Pancreatic ductal adenocarcinoma (PDAC)
3
RASolve 301
Phase 3 Multicenter, Open-Label, Randomized Study of Daraxonrasib (RMC‑6236) Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] Non-Small Cell Lung Cancer (NSCLC)
Active, RECRUITING
3 (open-label)
Non-small cell lung cancer (NSCLC)
3
RASolute 302*
Phase 3 Study of Daraxonrasib (RMC‑6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)
Active, NOT RECRUITING
3 (open-label)
Pancreatic ductal adenocarcinoma (PDAC), pancreatic cancer
3
RMC-LUNG-101
Study of RAS(ON) Inhibitor Combination or Monotherapy in Patients With Advanced RAS-mutated NSCLC
Active, RECRUITING
1b/2 (open-label)
Non-small cell lung cancer (NSCLC); KRAS, NRAS, HRAS mutant NSCLC; KRAS G12C mutant solid tumors, lung cancer; lung cancer stage IV, advanced solid tumor, cancer; RAS G12D mutant NSCLC
2
RMC-APEX-103
Study of Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) in Combination With Ivonescimab in Participants With Advanced or Metastatic RAS Mutant Solid Tumors
Active, RECRUITING
1/2 (open-label)
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), advanced solid tumors, metastatic solid tumors
2
RMC-5127-001
Study of RMC-5127 as Monotherapy and in Combination With Daraxonrasib (RMC-6236) or Cetuximab in Participants With Advanced KRAS G12V Mutant Solid Tumors
Active, RECRUITING
1/1b (open-label)
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors
1
RMC-9805-001
Study of Zoldonrasib (RMC-9805) in Participants With KRAS G12D Mutant Solid Tumors
Active, RECRUITING
1/1b (open-label)
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors
1
RMC-GI-102
Study of RAS(ON) inhibitors in Patients With Gastrointestinal Solid Tumors
Active, RECRUITING
1/2 (open-label)
Pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), gastrointestinal cancer
2
RMC-6291-101
Study of Elironrasib (RMC-6291) and Daraxonrasib (RMC-6236) as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C Mutant Solid Tumors
Active, RECRUITING
1b/2 (open-label)
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC)
2
RMC-6291-001
Dose Escalation and Dose Expansion Study of Elironrasib (RMC-6291) Monotherapy in Subjects With Advanced KRAS G12C Mutant Solid Tumors
Active, NOT RECRUITING
1/1b (open-label)
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors
1
RMC-6236-001
Study of Daraxonrasib (RMC-6236) in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Active, RECRUITING
1/2 (open-label)
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors
2
*As of 08/26/2026, daraxonrasib has been approved only in the United States. Daraxonrasib is a prescription medicine used to treat adults with a type of pancreatic cancer called pancreatic adenocarcinoma:
- who have received at least 1 prior treatment or who cannot receive a combination of cancer treatments.
The safety and efficacy of daraxonrasib has not been established by any other Regulatory Authority for this indication and for any other indication daraxonrasib remains investigational.
All other RAS(ON) inhibitors discussed are investigational and their safety and efficacy have not been established.
Discover all our active clinical trials in the complete list available here: ClinicalTrials.gov.
Daraxonrasib. Prescribing Information. Revolution Medicines, Inc.; 2026.